Posted by Michael Wonder on 06 Aug 2020
NICE supports use of new medicine for patients with malignant disease
5 August 2020 - Treosulphan is used as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation.
NICE has recommended the use of treosulphan in combination with fludarabine as an option for conditioning treatment before allogeneic haematopoietic stem cell transplant for people with malignant diseases for whom a reduced intensity regimen, such as low-dose busulphan with fludarabine, would be suitable.
Treosulphan with fludarabine is more effective and costs less than low-dose busulphan with fludarabine in most analyses. Therefore, treosulphan with fludarabine is recommended as an option in the NHS for conditioning treatment for people who would normally have a reduced intensity regimen.
